282 related articles for article (PubMed ID: 29708235)
1. Cutaneous Leishmaniasis: Update on Vaccine Development.
Whyte DC; Zufferey R
Hum Parasit Dis (Auckl); 2017; 9():. PubMed ID: 29708235
[TBL] [Abstract][Full Text] [Related]
2. Immune responses during cutaneous and visceral leishmaniasis.
Kedzierski L; Evans KJ
Parasitology; 2014 Jul; ():1-19. PubMed ID: 25075460
[TBL] [Abstract][Full Text] [Related]
3. [Cutaneous leishmaniasis in Germany-still a travel-related disease].
Talas J; Mielcarek K; Wu J; Brunner M; Steinhoff M; Zouboulis CC
Hautarzt; 2022 Feb; 73(2):146-151. PubMed ID: 34459942
[TBL] [Abstract][Full Text] [Related]
4. Particulate and non-particle adjuvants in Leishmaniasis vaccine designs: A review.
Kelleci K; Allahverdiyev A; Bağirova M; Ihlamur M; Abamor EŞ
J Vector Borne Dis; 2023; 60(2):125-141. PubMed ID: 37417162
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous and mucocutaneous leishmaniasis: Clinical perspectives.
Handler MZ; Patel PA; Kapila R; Al-Qubati Y; Schwartz RA
J Am Acad Dermatol; 2015 Dec; 73(6):897-908; quiz 909-10. PubMed ID: 26568335
[TBL] [Abstract][Full Text] [Related]
6. Leishmania Vaccines: the Current Situation with Its Promising Aspect for the Future.
Dinc R
Korean J Parasitol; 2022 Dec; 60(6):379-391. PubMed ID: 36588414
[TBL] [Abstract][Full Text] [Related]
7. Leishmania vaccines: progress and problems.
Kedzierski L; Zhu Y; Handman E
Parasitology; 2006; 133 Suppl():S87-112. PubMed ID: 17274851
[TBL] [Abstract][Full Text] [Related]
8. Genetically modified live attenuated parasites as vaccines for leishmaniasis.
Selvapandiyan A; Duncan R; Debrabant A; Lee N; Sreenivas G; Salotra P; Nakhasi HL
Indian J Med Res; 2006 Mar; 123(3):455-66. PubMed ID: 16778323
[TBL] [Abstract][Full Text] [Related]
9. Host immune response against leishmaniasis and parasite persistence strategies: A review and assessment of recent research.
Elmahallawy EK; Alkhaldi AAM; Saleh AA
Biomed Pharmacother; 2021 Jul; 139():111671. PubMed ID: 33957562
[TBL] [Abstract][Full Text] [Related]
10. Recent Advances in Vaccines Against Leishmania Based on Patent Applications.
Thomaz-Soccol V; Ferreira da Costa ES; Karp SG; Junior Letti LA; Soccol FT; Soccol CR
Recent Pat Biotechnol; 2018; 12(1):21-32. PubMed ID: 28494723
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous Leishmaniasis: A 2022 Updated Narrative Review into Diagnosis and Management Developments.
de Vries HJC; Schallig HD
Am J Clin Dermatol; 2022 Nov; 23(6):823-840. PubMed ID: 36103050
[TBL] [Abstract][Full Text] [Related]
12. Vaccination in Leishmaniasis: A Review Article.
Abdellahi L; Iraji F; Mahmoudabadi A; Hejazi SH
Iran Biomed J; 2022 Jan; 26(1):1-35. PubMed ID: 34952558
[TBL] [Abstract][Full Text] [Related]
13. An appraisal of the scientific current situation and new perspectives in the treatment of cutaneous leishmaniasis.
Briones Nieva CA; Cid AG; Romero AI; García-Bustos MF; Villegas M; Bermúdez JM
Acta Trop; 2021 Sep; 221():105988. PubMed ID: 34058160
[TBL] [Abstract][Full Text] [Related]
14. Transmission blocking vaccine studies in leishmaniasis: I. Lipophosphoglycan is a promising transmission blocking vaccine molecule against cutaneous leishmaniasis.
Tonui WK; Mbati PA; Anjili CO; Orago AS; Turco SJ; Githure JI; Koech DK
East Afr Med J; 2001 Feb; 78(2):84-9. PubMed ID: 11682952
[TBL] [Abstract][Full Text] [Related]
15. Vaccine candidates for leishmaniasis: a review.
Nagill R; Kaur S
Int Immunopharmacol; 2011 Oct; 11(10):1464-88. PubMed ID: 21616175
[TBL] [Abstract][Full Text] [Related]
16. Clinical and epidemiological characteristics of cutaneous leishmaniasis in Sri Lanka.
Iddawela D; Vithana SMP; Atapattu D; Wijekoon L
BMC Infect Dis; 2018 Mar; 18(1):108. PubMed ID: 29510669
[TBL] [Abstract][Full Text] [Related]
17. Sandfly Fever Sicilian Virus-Leishmania major co-infection modulates innate inflammatory response favoring myeloid cell infections and skin hyperinflammation.
Heirwegh E; MacLean E; He J; Kamhawi S; Sagan SM; Olivier M
PLoS Negl Trop Dis; 2021 Jul; 15(7):e0009638. PubMed ID: 34310619
[TBL] [Abstract][Full Text] [Related]
18. Protective or Detrimental? Understanding the Role of Host Immunity in Leishmaniasis.
Dos Santos Meira C; Gedamu L
Microorganisms; 2019 Dec; 7(12):. PubMed ID: 31847221
[TBL] [Abstract][Full Text] [Related]
19. Vaccination against cutaneous leishmaniasis: current status.
Melby PC
Am J Clin Dermatol; 2002; 3(8):557-70. PubMed ID: 12358557
[TBL] [Abstract][Full Text] [Related]
20. Association of Phlebotomus guggisbergi with Leishmania major and Leishmania tropica in a complex transmission setting for cutaneous leishmaniasis in Gilgil, Nakuru county, Kenya.
Owino BO; Matoke-Muhia D; Alraey Y; Mwangi JM; Ingonga JM; Ngumbi PM; Casas-Sanchez A; Acosta-Serrano A; Masiga DK
PLoS Negl Trop Dis; 2019 Oct; 13(10):e0007712. PubMed ID: 31626654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
